The scale of the microbial contribution is difficult to overstate. The intestinal microbiota contains a gene pool approximately 150 times larger than the human genome, dominated by four major phyla: Bacteroides, Firmicutes, Proteobacteria and Actinomycetes. The ratio of Firmicutes to Bacteroidetes has emerged as a recurring biomarker of microbial imbalance, or dysbiosis, across conditions ranging from obesity to hypertension. In health, the community operates in eubiosis, a balanced state in which microbes signal to host cells, train the immune system, protect against pathogens and regulate nutrient metabolism. When that balance collapses, the review finds, the consequences ripple far beyond the gut wall.

Technically, the microbiota’s influence flows through a small set of chemically well-defined metabolites. Fermentation of undigested carbohydrates by saccharolytic bacteria such as Bifidobacteria, Bacteroides, Faecalibacterium and Roseburia yields the short-chain fatty acids acetate, propionate and butyrate. These molecules bind G-protein-coupled receptors including GPR41, GPR43 and GPR109A on enteroendocrine and immune cells, triggering cAMP/PKA signaling that drives secretion of the satiety hormones GLP-1 and PYY, and inhibiting histone deacetylases to promote anti-inflammatory regulatory T cells. Bile acids, deconjugated in the colon by organisms such as Bacteroides intestinalis, signal through the nuclear receptor FXR and the membrane receptor TGR5 to regulate lipid metabolism and glucose homeostasis. Meanwhile, microbial metabolism of choline, carnitine and betaine generates trimethylamine, which the liver converts to trimethylamine N-oxide, or TMAO, a compound now firmly linked to cardiovascular risk.

The cardiovascular findings are among the most striking. Hypertensive patients show significant decreases in microbial diversity and richness and a markedly elevated Firmicutes-to-Bacteroidetes ratio, and a meta-analysis of eighteen observational studies found blood TMAO concentrations associated with hypertension risk in a dose-dependent manner. Mechanistically, TMAO activates the PERK unfolded-protein response in endothelial cells, provoking NF-κB-mediated inflammation and vascular dysfunction, while in macrophages it drives foam cell formation through CD36 upregulation. Animal experiments reinforce causality: transplanting stool from hypertensive patients into germ-free mice raises blood pressure, and antibiotic-mediated restoration of the Bacteroidetes-to-Firmicutes ratio relieves hypertension in rats. Microbial hydrogen sulfide adds another layer, since deficiency of this vasorelaxant gas precedes the onset of high blood pressure in spontaneously hypertensive rats.

Atherosclerosis tells a parallel story. Bacterial DNA has been recovered from atherosclerotic plaques, indicating that microbes or their products can reach the vessel wall, and a metagenome-wide association study found Enterobacter aerogenes significantly enriched in patients with atherosclerosis. Dysbiosis increases intestinal permeability, allowing lipopolysaccharide to enter the circulation and fuel vascular inflammation. Elevated TMAO accelerates macrophage-to-foam-cell conversion, impairs endothelial function and promotes platelet reactivity and thrombosis, while a second microbial metabolite, phenylacetylglutamine, enhances clotting through adrenergic G-protein-coupled receptors. Counterbalancing these harmful pathways, bile acids activate FXR to suppress inflammatory cytokine expression in monocytes and macrophages, and short-chain fatty acids promote vasorelaxation through cAMP-dependent signaling in the vascular endothelium.

The gut-brain axis occupies perhaps the most provocative territory in the review. In Parkinson’s disease, patients consistently show depletion of butyrate-producing genera such as Prevotella, Faecalibacterium and Butyricicella alongside expansions of Bifidobacteria and Enterococcus. Reduced short-chain fatty acid and ghrelin signaling appears to promote alpha-synuclein aggregation and overactivation of microglia, the brain’s resident immune cells. In a landmark germ-free mouse experiment, fecal microbiota transplanted from Parkinson’s patients worsened alpha-synuclein-driven motor deficits more than transplants from healthy donors, providing some of the strongest causal evidence that gut microbes can shape neurodegeneration. Alzheimer’s disease follows a similar logic: dysbiosis elevates pro-inflammatory taxa such as Escherichia and Shigella, and accumulation of microbial-derived phenylalanine and isoleucine expands pro-inflammatory Th1 cells that inflame the central nervous system.

Experimental interventions in Alzheimer’s models are particularly encouraging. APPPS1 mice raised germ-free show markedly reduced beta-amyloid deposition and microglial activation compared with conventionally raised animals, and transferring healthy microbiota into Alzheimer’s model mice improves amyloid and tau pathology, cognitive performance and glial reactivity. The prebiotic R13 has been shown to restrain amyloid aggregation in the gastrointestinal tract by modulating the C/EBPβ-AEP pathway, while the drug sodium oligomannate, or GV-971, remodels gut flora to prevent peripheral amino acid buildup and reduce neuroinflammation. The authors caution, however, that most human studies in Parkinson’s and Alzheimer’s are cross-sectional, confounded by medication such as levodopa, and marked by inconsistent findings across cohorts, so longitudinal and standardized studies remain essential.

Metabolic disease occupies the largest share of the evidence. In obesity, the microbiota of affected individuals shows reduced diversity with losses of Akkermansia muciniphila, Bacteroides and Faecalibacterium prausnitzii, and germ-free mice receiving obese-donor microbiota gain more fat than those receiving lean-donor communities. Short-chain fatty acids counter obesity through two routes: stimulating GLP-1 and PYY release to suppress appetite, and upregulating thermogenic and lipid-oxidation proteins including PPARγ, PGC1α, UCP1 and CPT-1. In diabetes, both type 1 and type 2 forms are associated with diminished microbial diversity, and microbiota-derived metabolites such as lipopolysaccharide and flagellin disrupt epithelial tight junctions and fuel insulin resistance. Non-alcoholic fatty liver disease completes the picture through the gut-liver axis, in which increased intestinal permeability permits endotoxin and even microbially produced endogenous ethanol to reach the liver, while butyrate activates the AMPK pathway to curb hepatic lipogenesis.

On the gastrointestinal front, inflammatory bowel disease features a characteristic collapse of Firmicutes and expansion of Proteobacteria, with fungal overgrowth also documented in Crohn’s disease, and transfer of dysbiotic microbes into germ-free mice reproduces colitis. In colorectal cancer, organisms such as Peptostreptococcus anaerobius and Fusobacterium nucleatum activate oncogenic signaling and suppress anti-tumor immunity, while microbial gallic acid can even flip mutant p53 between tumor-suppressive and cancer-promoting behavior depending on gut location. The review closes with a therapeutic roadmap: personalized probiotics guided by metagenomic sequencing, polyphenol- and fiber-rich diets to boost short-chain fatty acid production, narrow-spectrum antimicrobials that spare beneficial taxa, and fecal microbiota transplantation, which already cures recurrent Clostridium difficile infection and is being explored for obesity, inflammatory bowel disease and metabolic syndrome. The authors argue that integrating bioinformatics, organoid models and artificial intelligence will be the key to translating this microbial science from correlation into clinical practice.

Beyond the disease-specific findings, the review underscores how malleable the gut ecosystem is across a human lifetime. Composition shifts from birth through aging, and population studies consistently identify diet, geography, systemic illness and pharmaceutical exposure as dominant determinants of which taxa flourish. Antibiotic overuse emerges as a particular concern, since broad-spectrum agents can destabilize the eubiotic equilibrium and predispose the host to systemic disease, whereas a nutritious diet rich in fermentable substrates sustains communities that benefit the host.

The metabolic versatility of the resident microbes is central to this story. Colon-dwelling organisms preferentially consume carbohydrates that escape digestion in the upper tract, and when those substrates run short, bacteria switch to alternative energy sources that generate potentially harmful metabolites. This substrate-dependence explains why dietary pattern, not merely caloric intake, shapes the chemical signals reaching host tissues. The archaeon Methanobrevibacter smithii illustrates the ecosystem’s complexity: by converting hydrogen produced through bacterial fermentation into methane, it fine-tunes the fermentation environment in ways that influence overall energy harvest.

Microbes also participate in processing compounds the host cannot handle alone, including xenobiotics and drugs, a capacity with direct pharmacological implications. The review notes that microbial enzymes can alter drug metabolism, which may partly explain inter-individual variation in therapeutic response and adverse effects, an area the authors suggest deserves deeper integration into personalized medicine.

Methodologically, the field has had to overcome substantial obstacles. Early estimates of intestinal species richness were undercounts, driven by the difficulty of culturing many obligate anaerobes outside the body. Molecular and metagenomic approaches have since revealed the true diversity, and the authors argue that combining bioinformatics with organoid systems and machine learning will be essential to move from associative observations toward mechanistic, predictive models of microbe-host interaction.

On translation, the review strikes a measured tone. Fecal microbiota transplantation already stands as the clearest clinical success, effectively curing recurrent Clostridium difficile infection, while narrower applications for metabolic syndrome and inflammatory bowel disease remain under investigation. Personalized probiotics selected through sequencing, prebiotic fibers that feed beneficial saccharolytic taxa, polyphenol-rich diets, and narrow-spectrum antimicrobials designed to spare commensals together form a therapeutic toolkit that the authors believe could eventually shift clinical practice from treating dysbiosis after it appears toward maintaining eubiosis preventively, provided that rigorous longitudinal human studies validate the causal pathways suggested by animal work.

Subject of Research: Roles of the human gut microbiota and its metabolites in metabolic, neurodegenerative, cardiovascular and gastrointestinal diseases

Article Title: Roles of human gut microbiota in metabolic, neurodegenerative, cardiovascular and gastrointestinal diseases

Article References: Joshi, D., Chauhan, K., Oberoi, H. S., Kumar, D., & Taneja, N. K. (2026). Roles of human gut microbiota in metabolic, neurodegenerative, cardiovascular and gastrointestinal diseases. Discover Biotechnology, 3(1), Article 8. https://doi.org/10.1007/s44340-026-00053-2

Image Credits: AI Generated

DOI: 10.1007/s44340-026-00053-2

Keywords: gut microbiota, dysbiosis, short-chain fatty acids, TMAO, gut-brain axis, Parkinson's disease, Alzheimer's disease, hypertension, atherosclerosis, obesity, diabetes, fecal microbiota transplantation

The study investigates the complex interplay between gut health and brain function, underscoring the relevance of the gut-brain axis. This vital communication network between the gastrointestinal system and the central nervous system has garnered increasing attention in recent years, as emerging evidence suggests that gut flora can influence neural processes. Su et al. propose that restoring a healthy microbiome through FMT could mitigate the adverse effects of chronic cerebral hypoperfusion, a condition characterized by reduced blood flow to the brain.

Chronic cerebral hypoperfusion leads to a variety of neurological deficits, including memory impairment and decreased neurogenesis. The hippocampus, a key brain region associated with learning and memory, is particularly vulnerable to changes in cerebral blood flow. The researchers aimed to assess whether FMT could activate the Wnt signaling pathway, which is crucial for neurodevelopment and synaptic plasticity, thereby promoting neurogenesis in the hippocampus of rats subjected to chronic cerebral hypoperfusion.

To achieve this, the authors conducted a series of well-designed experiments, where they first established a model of chronic cerebral hypoperfusion in rats. Following this, they performed fecal microbiota transplants from healthy donor rats to the hypoperfused rats. Their assessments involved detailed analysis of hippocampal neuron proliferation and differentiation, employing sophisticated techniques such as immunohistochemistry and RNA sequencing.

The results were striking. After undergoing FMT, the rats not only exhibited a marked increase in the proliferation of neural progenitor cells in the hippocampus but also demonstrated enhanced synaptic integrity. These findings suggest that the beneficial alterations in gut microbiota following transplantation could stimulate the activation of the Wnt3a pathway, a key player in promoting cellular growth and differentiation within the brain.

One of the most remarkable aspects of this research is the identification of specific microbial species that appeared to drive these neurogenic effects. The study highlighted the selective enrichment of certain beneficial bacteria post-transplant, suggesting that a diverse and balanced gut microbiome is essential for optimal brain health. The authors speculate that these microbes may secrete metabolites capable of influencing brain function, thereby bridging the gap between gut health and neurogenesis.

Additionally, the study contributes to an evolving narrative about the potential of non-invasive therapies in neurological conditions. While traditional pharmacological approaches often focus on symptom management, this research points toward innovative methods that target the root causes of cognitive decline. By harnessing the power of gut microbiota, FMT could pave the way for novel treatments in patients suffering from neurodegenerative conditions or cognitive impairments linked to vascular health.

The implications of these findings extend beyond animal models, sparking curiosity about the potential for similar therapeutic effects in humans. While clinical trials are essential for validating these results in human populations, the promise of utilizing gut microbiota to enhance cognitive function is an exciting frontier in neuroscience. The prospect of developing microbiota-based therapies could revolutionize how doctors approach neurodegenerative diseases.

Moreover, this study raises important questions about diet, lifestyle, and their effects on gut health and, consequently, brain health. As research continues to elucidate the connections between the microbiome and neural processes, it becomes increasingly clear that a holistic approach to health is vital. Personalized nutrition and microbiome management could become key strategies in promoting not only gut health but also cognitive resilience.

Furthermore, the findings emphasize the need for greater public awareness regarding the complexities of gut microbiota and its far-reaching implications for mental health and cognitive function. As the stigma surrounding mental health continues to diminish, educating individuals about the role of their gut health in overall well-being is paramount. It encourages a proactive approach to maintaining a balanced lifestyle that includes a diverse diet rich in prebiotics and probiotics.

The story does not end here. Ongoing research will undoubtedly delve deeper into the molecular mechanisms behind these observations, exploring the potential of targeting specific microbial communities to facilitate neurogenesis. Future studies may uncover additional pathways influenced by gut microbiota, further unraveling the intricate connections between our gut and brain.

The research led by Su et al. stands as a testament to the importance of interdisciplinary collaboration in science. Bridging the fields of microbiology, neuroscience, and nutrition, this study exemplifies how innovative thinking can yield transformative insights into complex biological systems. It serves as a reminder of the extensive potential that lies in understanding and harnessing the microbiome for health benefits.

As we move forward into an era where personalized medicine becomes increasingly viable, findings like these will play a crucial role in shaping future therapeutic protocols. With the promise of fecal microbiota transplantation gaining traction, clinicians may soon find themselves equipped with novel tools to address cognitive decline among patients and advocate for preventive strategies aimed at preserving brain health.

In conclusion, the pioneering work of Su et al. highlights a hopeful future where understanding the gut microbiome could lead to groundbreaking interventions for cognitive impairment and neurodegenerative diseases. As scientists unravel the complexities of the gut-brain axis, the potential to transform patient care and improve quality of life becomes increasingly tangible.

In summary, the research demonstrates that fecal microbiota transplantation not only improves gut health but may also lead to significant advancements in neurogenesis and cognitive function. This multifaceted relationship showcases the untapped therapeutic potential of leveraging gut microbiota for neurological benefits. Researchers and healthcare professionals alike should continue to explore this exciting domain, ensuring that future generations benefit from enhanced understanding and innovative solutions for brain health.

Subject of Research: Fecal microbiota transplantation and its effects on hippocampal neurogenesis in chronic cerebral hypoperfusion.

Article Title: Fecal microbiota transplantation promotes Wnt3a-mediated hippocampal neurogenesis in a rat model of chronic cerebral hypoperfusion.

Article References:

Su, SH., Lu, DD., Wu, YF. et al. Fecal microbiota transplantation promotes Wnt3a-mediated hippocampal neurogenesis in a rat model of chronic cerebral hypoperfusion. J Transl Med (2026). https://doi.org/10.1186/s12967-025-07631-8

Image Credits: AI Generated

DOI: 10.1186/s12967-025-07631-8

Keywords: fecal microbiota transplantation, neurogenesis, Wnt3a, hippocampus, chronic cerebral hypoperfusion, gut-brain axis, cognitive decline, microbiome, neuroscience.

Immune checkpoint inhibitors have redefined therapeutic paradigms by unleashing the immune system’s latent capacity to recognize and annihilate cancer cells. However, resistance to ICIs remains a critical bottleneck in clinical success, with many patients experiencing suboptimal responses or relapse. Mounting evidence implicates the gut microbiome—an extraordinarily diverse and dynamic ecosystem of trillions of microorganisms—in modulating immune function and influencing therapeutic outcomes. FMT, the transfer of fecal material containing microbial communities from healthy donors to patients, has surfaced as a compelling strategy to recalibrate impaired microbiota and restore immune responsiveness, yet its clinical application in oncology is fraught with complexities.

Dr. Luo emphasizes that the impact of FMT on enhancing ICI therapy is far from uniform. “Our review highlights a spectrum of responses — ranging from striking clinical remission in certain melanoma patients to unexpected adverse outcomes in others,” he explains. Some landmark melanoma studies demonstrate that approximately 40% of patients who previously showed resistance to immunotherapy regained sensitivity post-FMT, a finding that ignited optimism for microbiome-centered interventions. However, contradictory trials reveal that specific bacterial consortia delivered via FMT can paradoxically dampen immune activation, emphasizing that the microbial realm is not a one-size-fits-all remedy but rather a highly individualized and complex influencer of cancer immunology.

Central to the review’s insights is the recognition that the gut microbiome functions as an intricate ecological network, where compositional and functional attributes of microbial taxa orchestrate distinct immunomodulatory effects. Beneficial commensals have been shown to potentiate cytotoxic T cell activity and facilitate infiltration of effector immune cells into the tumor microenvironment. Conversely, adverse bacteria may foster regulatory immune populations, such as myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs), which blunt antitumor immunity and promote tumor persistence. These antagonistic interactions underscore the challenge of engineering microbial consortia that predictably augment immunotherapy.

Moreover, individual patient factors, including baseline microbiome diversity, genetic predispositions, diet, and concurrent medications, intricately influence FMT outcomes. “We were particularly surprised by the observation that identical bacterial species can exert diametrically opposed effects depending on host context,” notes Dr. Luo. This revelation pinpoints the paramount necessity for personalized microbiome therapeutics that accommodate the host’s unique biological landscape rather than indiscriminately applying generalized microbial formulations.

Another pivotal aspect highlighted in the review concerns donor selection criteria. The choice of donor microbiota emerges as a critical determinant of therapeutic success or failure. Donors with high microbial diversity and enriched populations of immunostimulatory bacteria tend to produce superior clinical outcomes. Nonetheless, the absence of standardized donor screening protocols and microbial characterization methodologies presents a significant hurdle in developing reproducible and reliable FMT-based immunotherapy adjuvants.

The authors also discuss the underlying mechanistic pathways through which gut bacteria interface with immune checkpoint blockade. Specific microbial metabolites, such as short-chain fatty acids (SCFAs), and bacterial-derived molecular patterns engage pattern recognition receptors on immune cells, modulating downstream signaling pathways that either prime antitumor immunity or facilitate immune evasion. Metabolomic and transcriptomic profiling of patient samples pre- and post-FMT further unravel the complex crosstalk between microbial metabolic outputs and host immune gene expression networks.

From a translational perspective, the review strongly advocates for the initiation of large-scale, multicenter clinical trials to systematically evaluate FMT efficacy and safety in conjunction with ICIs across diverse cancer types. Such trials must integrate rigorous microbiome sequencing, immune phenotyping, and functional assays to delineate biomarkers predictive of response and adverse events. Integration of computational models to predict optimal donor-recipient microbial matches could revolutionize patient stratification and treatment personalization.

Emerging technological advances in synthetic biology and microbial engineering offer tantalizing prospects to refine FMT approaches. Designer microbial consortia, genetically optimized to amplify antitumor immune mechanisms while minimizing off-target effects, represent the next evolutionary step beyond crude fecal transfers. Such innovations may overcome current limitations by allowing precise modulation of key immunological pathways and tumor microenvironment conditioning.

Safety considerations remain paramount, given the potential risks associated with transferring pathogenic or deleterious bacteria. The review calls for the development of standardized protocols encompassing donor screening, microbial characterization, and post-treatment monitoring to mitigate risks. Regulatory frameworks must evolve concurrently to oversee the clinical deployment of microbiome-based therapeutics and ensure patient protection.

As the field advances, Dr. Luo envisions a future where oncologists harness the gut microbiome as a precision tool, integrated seamlessly with conventional immunotherapies to transform cancer treatment outcomes. “Our findings illustrate a journey from chaos to order in the realm of fecal microbiota transplantation, highlighting the imperative for nuanced, scientifically grounded approaches to unlock its full potential,” he concludes.

This rigorous review represents a critical inflection point in cancer immunology, offering a roadmap for translating microbiome science into tangible clinical benefits. By elucidating the multifaceted influences of gut bacteria on immune checkpoint inhibitor efficacy, it sets the stage for a new era of microbiome-informed, patient-centric cancer therapies aimed at conquering resistance and achieving durable remissions.

Subject of Research: Cells
Article Title: From chaos to order: optimizing fecal microbiota transplantation for enhanced immune checkpoint inhibitors efficacy.
Web References: http://dx.doi.org/10.1080/19490976.2025.2452277
Keywords: Cancer immunoediting